Print page content Print
Increase text size Decrease text size
Text Size


Type A Medicated Article


BMD® is a Type A Medicated Article for the prevention and control of necrotic enteritis, increased rate of weight gain and improved feed efficiency in poultry.

  • By controlling necrotic enteritis, BMD preserves the integrity of the gut wall, helping to ensure the absorption of nutrients from feed1
  • Not absorbed from the intestinal tract, thus no withdrawal period needed2
  • Patented Chilsonation process produces free-flowing, dust-free granules to improve flowability and stability to ensure proper dosage
  • Reduces subclinical and clinical disease, resulting in greater productivity and decreased morbidity/mortality
  • Consistent performance after many years of use
  • BMD is not included in the FDA/CVM list of medically important antibiotics for human health3
Collapse All
    • Aids in the prevention and control of necrotic enteritis in chickens caused or complicated by Clostridium spp. and as an aid in the control of transmissible enteritis in growing turkeys
    • For prevention of ulcerative enteritis in quail caused by Clostridium colinum
    • For increased rate of weight gain and improved feed efficiency in chickens, turkeys, pheasants and quail
    • For increased egg production and improved feed efficiency in laying hens during the first seven months of production
  • FDA Status:

    • Category I drug and does not require a feedmill license for manufacture of medicated feeds
    • Approved for use in combination with Avatec®, Deccox®, Robenz® and Zoamix®*

    Storage and Packaging:

    • Store in a protected location, avoid excessive heat and keep package closed to avoid contamination
    • BMD is packaged in a 50-pound, multiwall paper bag with protective barrier ply

    *Reference Title 21 Code of Federal Regulations 558.76 for species-specific combination clearances.

    • Expiration period is 30 months from the date of manufacture (package indicates expiration date)
    • For use in the manufacture of medicated animal feeds
    • For use in dry feeds only
    • Not for use in Liquid Type B Medicated Feeds
  • Necrotic enteritis, control of transmissible enteritis and the prevention of ulcerative enteritis

    1. Miller SH, Skinner J, Davis SW. Efficacy of Probiotic and/or BMD® in the Feed for Control of Necrotic Enteritis Caused by Clostridium perfringens in Broiler Chickens. Zoetis Global Poultry. Data on file.
    2. Original New Animal Drug Application (Bacitracin methylene disalicylate – BMD®). NADA 141-153. Food and Drug Administration, Center for Veterinary Medicine, January 13, 2000.
    3. FDA Guidance for Industry #152. Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern. Food and Drug Administration, Center for Veterinary Medicine, October 23, 2003.


For Use in Animals Only.
For Use in Dry Feeds Only.
Not for Use in Liquid Type B Medicated Feeds.



Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.